Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Drug that boosts activity in the brain's 'garbage disposal' system may slow Alzheimer's disease

A drug that boosts activity in the brain's "garbage disposal" system can decrease levels of toxic proteins associated with Alzheimer's disease and other neurodegenerative disorders and improve cognition in mice, a new study by neuroscientists at Columbia University Medical Center has found.

22 Dec 2015

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.

21 Dec 2015

$Role for carfilzomib in relapsed, refractory multiple myeloma treatment$

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

Carfilzomib significantly improves outcomes in previously treated patients with relapsed or refractory multiple myeloma, shows a head-to-head comparison with bortezomib.

11 Dec 2015

BioLight announces first sale of IOPtiMate system in Portugal

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate system to a medical center located in Portugal.

8 Dec 2015

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Takeda Pharmaceutical Company Limited today announced results from the TOURMALINE-MM1 trial presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), showing that treatment with NINLARO (ixazomib) capsules is effective in extending progression free survival (PFS) with a manageable tolerability profile in patients with relapsed and/or refractory multiple myeloma.

8 Dec 2015

Lancet study compares prices of new cancer drugs in high-income countries

The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.

8 Dec 2015

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments.

8 Dec 2015

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers.

7 Dec 2015

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

7 Dec 2015

Yale study identifies how myeloma cells escape treatment

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence.

7 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

SkylineDx's MMprofiler receives CE-IVD certification

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler, the company's prognostic test to determine the level of risk of a patient with multiple myeloma (MM).

25 Nov 2015

BioLight signs joint financing agreement with two Asia-based venture capital firms

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement.

25 Nov 2015

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration has approved NINLARO (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

25 Nov 2015

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

The Leukemia & Lymphoma Society applauds the FDA's recent approval of two new drugs -- daratumumab and ixazomib -- to treat patients with relapsed multiple myeloma. These therapies are the latest in a growing arsenal to fight this blood cancer that impacts nearly 100,000 patients in the U.S. Advances in treatments for many different types of blood cancers are happening with dizzying speed and these two approvals in just one week are the latest evidence of this phenomenon.

23 Nov 2015

New drug screening method may predict treatment options for patients with multiple myeloma

A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process, developed by scientists at Washington University School of Medicine in St. Louis, also may aid patients with leukemia or lymphoma.

21 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.

13 Nov 2015

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Drug that boosts activity in the brain's 'garbage disposal' system may slow Alzheimer's disease

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Role for carfilzomib in relapsed, refractory multiple myeloma treatment

BioLight announces first sale of IOPtiMate system in Portugal

Takeda presents Phase 3 TOURMALINE-MM1 data for multiple myeloma at ASH 2015

Lancet study compares prices of new cancer drugs in high-income countries

Study shows promise for cord blood-derived natural killer cells in multiple myeloma patients

New approaches to treating leukemia, lymphoma and myeloma

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

Yale study identifies how myeloma cells escape treatment

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

SkylineDx's MMprofiler receives CE-IVD certification

BioLight signs joint financing agreement with two Asia-based venture capital firms

Takeda receives FDA approval for NINLARO (ixazomib) capsules to treat patients with multiple myeloma

Leukemia & Lymphoma Society applauds FDA's recent approval of two new multiple myeloma drugs

New drug screening method may predict treatment options for patients with multiple myeloma

Ninlaro (ixazomib) approved to treat people with multiple myeloma

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in